| Alpha emitter radium-223 and survival in metastatic prostate cancer C Parker, S Nilsson, D Heinrich, SI Helle, JM O'Sullivan, SD Fosså, ... New England Journal of Medicine 369 (3), 213-223, 2013 | 3648 | 2013 |
| Clinical features of metastatic bone disease and risk of skeletal morbidity RE Coleman Clinical cancer research 12 (20), 6243s-6249s, 2006 | 2707 | 2006 |
| Metastatic bone disease: clinical features, pathophysiology and treatment strategies RE Coleman Cancer treatment reviews 27 (3), 165-176, 2001 | 2374 | 2001 |
| Skeletal complications of malignancy RE Coleman Cancer: Interdisciplinary International Journal of the American Cancer …, 1997 | 2026 | 1997 |
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial I Smith, M Procter, RD Gelber, S Guillaume, A Feyereislova, M Dowsett, ... The lancet 369 (9555), 29-36, 2007 | 1953 | 2007 |
| Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women … P McGale, C Taylor, C Correa, D Cutter, F Duane, M Ewertz, R Gray, ... Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews …, 2014 | 1858* | 2014 |
| The clinical course of bone metastases from breast cancer RE Coleman, RD Rubens British journal of cancer 55 (1), 61-66, 1987 | 1421 | 1987 |
| Adjuvant docetaxel for node-positive breast cancer M Martin, T Pienkowski, J Mackey, M Pawlicki, JP Guastalla, C Weaver, ... New England Journal of Medicine 352 (22), 2302-2313, 2005 | 1341 | 2005 |
| Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind … LS Rosen, D Gordon, M Kaminski, A Howell, A Belch, J Mackey, ... Cancer journal (Sudbury, Mass.) 7 (5), 377-387, 2001 | 1198 | 2001 |
| Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or … LS Rosen, D Gordon, M Kaminski, A Howell, A Belch, J Mackey, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2003 | 1094 | 2003 |
| Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial RC Coombes, LS Kilburn, CF Snowdon, R Paridaens, RE Coleman, ... The Lancet 369 (9561), 559-570, 2007 | 1092 | 2007 |
| Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial MR Smith, F Saad, R Coleman, N Shore, K Fizazi, B Tombal, K Miller, ... The Lancet 379 (9810), 39-46, 2012 | 985 | 2012 |
| Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials B Asselain, W Barlow, J Bartlett, J Bergh, E Bergsten-Nordström, J Bliss, ... The Lancet Oncology 19 (1), 27-39, 2018 | 896 | 2018 |
| Adjuvant ovarian suppression in premenopausal breast cancer PA Francis, MM Regan, GF Fleming, I Láng, E Ciruelos, M Bellet, ... New England Journal of Medicine 372 (5), 436-446, 2015 | 845 | 2015 |
| Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. W ten Bokkel Huinink, M Gore, J Carmichael, A Gordon, J Malfetano, ... Journal of Clinical Oncology 15 (6), 2183-2193, 1997 | 834 | 1997 |
| Phase III randomized trial of docetaxel–carboplatin versus paclitaxel–carboplatin as first-line chemotherapy for ovarian carcinoma PA Vasey, GC Jayson, A Gordon, H Gabra, R Coleman, R Atkinson, ... Journal of the National Cancer Institute 96 (22), 1682-1691, 2004 | 792 | 2004 |
| Pathologic fractures correlate with reduced survival in patients with malignant bone disease F Saad, A Lipton, R Cook, YM Chen, M Smith, R Coleman Cancer 110 (8), 1860-1867, 2007 | 734 | 2007 |
| Zoledronic acid reduces skeletal‐related events in patients with osteolytic metastases: A double‐blind, randomized dose–response study JR Berenson, LS Rosen, A Howell, L Porter, RE Coleman, W Morley, ... Cancer 91 (7), 1191-1200, 2001 | 678 | 2001 |
| Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors JE Brown, RJ Cook, P Major, A Lipton, F Saad, M Smith, KA Lee, M Zheng, ... Journal of the National Cancer Institute 97 (1), 59-69, 2005 | 671 | 2005 |
| Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid RE Coleman, P Major, A Lipton, JE Brown, KA Lee, M Smith, F Saad, ... Journal of Clinical Oncology 23 (22), 4925-4935, 2005 | 650 | 2005 |
